louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03836846: Social Media Use in Adolescents Admitted to a Psychiatric Unit
Official title: Social Media Use in Adolescents Admitted to a Psychiatric Unit
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Depression
Social Media
Adolescent Behavior
Lead sponsor: Kaiser Permanente
Sponsor class: OTHER
First posted: 2019-02-11
Enrollment: 0
Sex: ALL
Minimum age (years): 13
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: We will investigate the association between social media use and depression in adolescents admitted to a psychiatric unit and continue to follow their progress after discharge in outpatient clinic services. We expect improvement in their depressive symptoms by modifying social media use and adding a mental health app to further encourage the positive effects of social media.


Eligibility criteria: Inclusion Criteria:

* Participants admitted to inpatient psychiatric unit
* Kaiser insured participants between 13-17 years of age with parental consent
* positive for social media use
* English speaking

Exclusion Criteria:

* pregnant
* non English speaking

Primary outcomes:
measure: Comparing depression scale,PHQ9-A (Patient Health Questionnaire, Adolescent Version), with social media use
timeFrame: 1 month
measure: Comparing depression scale,PHQ9-A (Patient Health Questionnaire, Adolescent Version), with social media use
timeFrame: 3 months
measure: Comparing depression scale,PHQ9-A (Patient Health Questionnaire, Adolescent Version), with social media use
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Chino
country: United States
facility: Canyon Ridge Hospital
state: California
Study officials:
References:
citation: Pantic I. Online social networking and mental health. Cyberpsychol Behav Soc Netw. 2014 Oct;17(10):652-7. doi: 10.1089/cyber.2014.0070. Epub 2014 Sep 5.
citation: Luxton DD, June JD, Fairall JM. Social media and suicide: a public health perspective. Am J Public Health. 2012 May;102 Suppl 2(Suppl 2):S195-200. doi: 10.2105/AJPH.2011.300608. Epub 2012 Mar 8.
citation: Banos RM, Etchemendy E, Mira A, Riva G, Gaggioli A, Botella C. Online Positive Interventions to Promote Well-being and Resilience in the Adolescent Population: A Narrative Review. Front Psychiatry. 2017 Jan 30;8:10. doi: 10.3389/fpsyt.2017.00010. eCollection 2017.
Clinical trial NCT01611246: Earset Healthy Volunteer Study
Official title: Performance of the Acclarent Iontophoresis System With Earset (IPSES) in Healthy Volunteers
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Otitis Media
Lead sponsor: Integra LifeSciences Corporation
Sponsor class: INDUSTRY
Collaborators: name: Acclarent
First posted: 2012-06-04
Enrollment: 22
Sex: ALL
Minimum age (years): 12
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes

Brief summary: The study will recruit healthy volunteers to undergo the Iontophoresis procedure using the Acclarent Iontophoresis System with Earset (IPSES).


Eligibility criteria: Inclusion Criteria:

* At least 12 months old

Exclusion Criteria:

* Pregnant or lactating females
* Subjects with history of sensitivity or reaction to lidocaine, tetracaine, epinephrine, or any hypersensitivity to local anesthetics of the amide type, or any component of the drug solution
* Significantly atrophic or perforated tympanic membrane
* Otitis externa
* Damaged or denuded skin in the auditory canal
* Electrically sensitive subjects and subjects with electrically sensitive support systems (pacemakers, defibrillators, etc.)
* Cerumen impaction resulting in a significant amount of cleaning required to visualize the tympanic membrane
* Evidence of Otitis Media at day of procedure, or within the past three (3) months prior to procedure.

Primary outcomes:
measure: Number of subjects anesthetized as assessed by Wong-Baker scale
timeFrame: Day 1
Secondary outcomes:
measure: Number of participants with serious adverse events
timeFrame: Day 1
Other outcomes:
Locations:
city: East Palo Alto
country: United States
facility: CEI Medical Group
state: California
Study officials:
affiliation: CEI Medical Group
name: Joseph Roberson, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04581746: Impact of the Epidemic of COVID-19 Infection Among People Living With HIV (SARS-CoV-2)
Official title: Evaluation of the Impact of the Epidemic of COVID-19 Infection Among People Living With HIV (SARS-CoV-2)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Virus-HIV
Covid19
Lead sponsor: Tourcoing Hospital
Sponsor class: OTHER
First posted: 2020-10-09
Enrollment: 1800
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: The non-essential and non-urgent follow-up consultations of patients living with HIV were postponed or transformed into "teleconsultation" or exchanges of e-mails between practitioners and patients during COVID-19 epidemic. This change in care can have an impact on follow-up and access to treatment for PVVIH.

Detailed description: On 16 March 2020, an instruction to postpone "non-urgent" consultations was given to doctors. Thus, the non-essential and non-urgent follow-up consultations of patients living with HIV were postponed or transformed into "teleconsultation" or exchanges of e-mails between practitioners and patients. This change in care can have an impact on follow-up and access to treatment for PVVIH. In addition, the epidemic itself may have consequences: PVVIH may be at greater risk because of their immunosuppression and associated co-morbidities.

Eligibility criteria: Inclusion Criteria:

* Patient followed up for HIV infection in one of the COREVIH Hauts de France centres participating in the study
* Having communicated an email address
* Having given their consent to participate in this study
* Beneficiary subject affiliated or entitled to a social security scheme

Exclusion Criteria:

* Minor patient
* Refusal to participate
* Patient under guardianship

Primary outcomes:
measure: Prevalence of SARS CoV2 infection in PVVIH in Hauts de France
timeFrame: Inclusion
Secondary outcomes:
measure: Prevalence of SARS CoV2 infection in PVVIH in Hauts de France
timeFrame: through study completion, an average of 19 months
measure: Determine the incidence rate of COVID 19 among PVVIH antiretroviral treatment
timeFrame: through study completion, an average of 19 months
measure: Determine the incidence rate of COVID 19 among PVVIH discontinuing antiretroviral treatment
timeFrame: through study completion, an average of 19 months
measure: Determine the incidence rate of COVID 19 among PVVIH who stopped all follow-up
timeFrame: through study completion, an average of 19 months
measure: Psychological consequences of this epidemic among PVVIH : HAD
timeFrame: through study completion, an average of 19 months
measure: Psychological consequences of this epidemic among PVVIH : PROQOL-HIV
timeFrame: through study completion, an average of 19 months
Other outcomes:
Locations:
city: Amiens
country: France
facility: CHU Amiens Picardie
city: Lens
country: France
facility: CH Lens
city: Tourcoing
country: France
facility: CH Tourcoing
Study officials:
affiliation: CH TOURCOING
name: Pauline THILL, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03663946: A Study to Observe the Onset of Immune-related Adverse Reactions in Patients With Non-surgical or Renal Cell Carcinoma (RCC) That Has Spread
Official title: Drug Use Investigation on Combination Therapy With Yervoy and Opdivo (Unresectable or Metastatic Renal Cell Carcinoma)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Renal Cell Carcinoma
Kidney Cancer
Lead sponsor: Bristol-Myers Squibb
Sponsor class: INDUSTRY
First posted: 2018-09-10
Enrollment: 81
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with unresectable or metastatic renal cell carcinoma who are initiating treatment for the first time with Yervoy and Opdivo

Brief summary: Patients with non-surgical or renal cell carcinoma that has spread who are starting treatment for the first time with Yervoy and Opdivo in the real world


Eligibility criteria: Inclusion Criteria:

* Patients with unresectable or metastatic renal cell carcinoma who are initiating treatment for the first time with Yervoy and Opdivo in accordance with the Japanese package insert will be included in this PMS

Exclusion Criteria:

* Patients receiving combination therapy with Yervoy and Opdivo for non RCC indication will be excluded from this PMS

Other protocol defined inclusion/exclusion criteria could apply

Primary outcomes:
measure: Incidence of immune-related AE's
timeFrame: Approximately 13 weeks
measure: Incidence of immune related SAE's
timeFrame: Approximately 13 weeks
Secondary outcomes:
measure: Incidence of treatment for immune-related adverse reactions
timeFrame: Approximately 13 weeks
measure: Incidence of unknown AE's
timeFrame: Approximately 13 weeks
measure: Incidence of unknown SAE's
timeFrame: Approximately 13 weeks
Other outcomes:
Locations:
city: Tokyo
country: Japan
facility: Local Institution
Study officials:
affiliation: Bristol-Myers Squibb
name: Bristol-Myers Squibb
role: STUDY_DIRECTOR
References:
Clinical trial NCT06422546: A Prospective, Multicenter, Non-interventional, Real-world Study to Characterize Changes in Molecular Markers After Three Weeks of Targeted Therapy With Oxitinib in EGFRm NSCLC
Official title: A Prospective, Multicenter, Non-interventional, Real-world Study to Characterize Changes in Molecular Markers After Three Weeks of Targeted Therapy With Oxitinib in Chinese Patients With Stage IV Metastatic or Recurrent Non-squamous EGFR-positive NSCLC
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Non Small Cell Lung Cancer
Lead sponsor: Beijing Cancer Prevention & Treatment Society
Sponsor class: OTHER
Collaborators: name: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
First posted: 2024-05-21
Enrollment: 950
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: stage IV metastatic or recurrent non-squamous EGFR-positive NSCLC

Brief summary: To evaluate the characteristics of genetic variationmutations at baseline and 3 weeks after oxitinib treatment in EGFRm NSCLC

Detailed description: Characteristics of EGFR gene mutation and efficacy of oxitinib treatment at baseline and after 3 weeks of treatment.To evaluate the mechanism of oxitinib treatment resistance and describe the characteristics of genetic variation associated with oxitinib treatment at baseline and 3 weeks after treatment.

Eligibility criteria: Inclusion Criteria:

1. ≥18 years old male or female
2. Stage IV metastatic or recurrent non-squamous NSCLC that is newly diagnosed, histologically proven and not suitable for radical surgery or radiotherapy (AJCC V8);
3. Without prior systemic antitumor therapy including EGFR-TKI or immunotherapy;
4. EGFR positive in blood or tissue tested in local laboratory;
5. Sufficient blood samples can be provided for molecular detection;
6. Signed informed consent forms are available.

Exclusion Criteria:

1. Patients were unable to collect plasma samples at baseline;
2. The EGFR mutant status of the patient's blood specimen at baseline has not been verified by the central laboratory;
3. The patient refused subsequent treatment with oxitinib; 4）The investigator determines that may affect the conduct of the clinical study and the judgement of the study results.

Primary outcomes:
measure: changes in EGFR gene mutations
timeFrame: baseline and 3 weeks after oxitinib treatment
Secondary outcomes:
measure: Characteristics of EGFR gene mutation and efficacy of oxitinib treatment
timeFrame: baseline and 3 weeks after oxitinib treatment
Other outcomes:
measure: describe the characteristics of genetic variation associated with oxitinib treatment
timeFrame: baseline and 3 weeks after oxitinib treatment
Locations:
city: Beijing
country: China
facility: Beijing Cancer Prevention society
state: Beijing
Study officials:
References:
Clinical trial NCT00465946: Effect of Dietary Salt Supplemantation in Vasovagal Syncope Prophylaxis: A Clinical Trial
Official title: Effect of Dietary Salt Supplemantation in Vasovagal Syncope Prophylaxis: A Clinical Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Healthy
Keywords: Salt supplementation
Vasovagal syncope
Orthostatic tolerance
Healthy volunteers
Lead sponsor: Hospital de Clinicas de Porto Alegre
Sponsor class: OTHER
First posted: 2007-04-27
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: PREVENTION

Brief summary: Syncope is a syndrome consisting of a relatively short period of temporary and self-limited loss of consciousness caused by transient diminution of blood flow to the brain (most often the result of systemic hypotension). The objective of this study was to evaluate the effect of salt supplementation in vasovagal syncope prophylaxis.

Detailed description: Healthy volunteers without use of medicines with except contraceptives orals that met the exclusion criteria were consecutively enrolled in a randomized trial.

Eligibility criteria: Inclusion Criteria:

* Healthy volunteers

Exclusion Criteria:

* Use medicines
* Previous diseases
* Incapacity of to understand and to sign the term consent

Primary outcomes:
measure: Evaluate the effectiveness of the salt supplementation in the prophylaxis of the vasovagal syncope
Secondary outcomes:
measure: Evaluate the supplementation salt increases the orthostatic tolerance
measure: Analyze the supplementation salt increases the plasmatic volume
Other outcomes:
Locations:
city: Porto Alegre
country: Brazil
facility: Hospital de Clínicas de Porto Alegre
state: Rio Grande do Sul
Study officials:
affiliation: Associate Professor
name: Leandro I Zimerman, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06814912: Evaluation of Virtual Reality Headsets on Cancer Patients During Day Hospital Stay
Official title: Prospective Evaluation of Virtual Reality Headsets on Cancer Patients During Day Hospital Stay
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cancer
Lead sponsor: Institut Sainte Catherine
Sponsor class: OTHER
First posted: 2025-02-07
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: Use of virtula reality headsets during treatment course on day hospitalized cancer patients


Eligibility criteria: Inclusion Criteria:

* cancer patients
* chemotherapy treatment

Exclusion Criteria:

-

Primary outcomes:
measure: Rate of patients with nausea reduction compared with preview treatment administration
timeFrame: From the first chemotherapy injection until the end of chemotherapy injection with the virtual reality headset (at the end of the third cycle; each cycle is 21 days) )
Secondary outcomes:
Other outcomes:
Locations:
city: Avignon
country: France
facility: ICAP
Study officials:
References:
Clinical trial NCT02125812: Adjunctive Systemic Administration of Moxifloxacin in the Treatment of Aggressive Periodontitis
Official title: Adjunctive Systemic Administration of Moxifloxacin in the Treatment of Aggressive Periodontitis: Double-blind Controlled Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Aggressive Periodontitis
Keywords: Aggressive Periodontitis
antimicrobial(s)
microbiology
Lead sponsor: Facultad Nacional de Salud Publica
Sponsor class: OTHER
Collaborators: name: Universidad de Antioquia
First posted: 2014-04-29
Enrollment: 40
Sex: ALL
Minimum age (years): 15
Maximum age (years): 30
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The adjunctive use of systemically administered antibiotics has been shown to provide a better clinical outcome, particularly in terms of probing depth (PD) reduction and attachment-level gain than SRP in subjects with Aggressive Periodontitis.

The overall objective of this study is to evaluate the clinical and microbiological efficacy of moxifloxacin as an adjunct to scaling and root planing versus scaling and root planing over placebo in the treatment of aggressive periodontitis.


Eligibility criteria: Inclusion Criteria:

* under 30 years old and systemically healthy, with at least 20 teeth present. Be willing to participate in the study which is corroborated by signing the informed consent form.

Commit to attend post-therapeutic controls and stop drinking alcohol during the time of ingestion of antibiotics.

Exclusion Criteria:

* Subjects in whom are contraindicated or with hypersensitivity to quinolones - Subjects who have undergone periodontal, surgical or mechanical antibiotic therapy six months before the start of the study according to interrogation.

Women in pregnancy or lactation, corroborated with previous medical history and medical consultation.

Primary outcomes:
measure: probing depth
timeFrame: six months
Secondary outcomes:
measure: clinical attachment level and probing depth
timeFrame: 6 moths
Other outcomes:
Locations:
city: Departamento de Antioquia
country: Colombia
facility: Faculty of Dentistry
state: Medellin
Study officials:
affiliation: Universidad de Antioquia
name: Carlos M Ardila, Ph.D
role: PRINCIPAL_INVESTIGATOR
References:
citation: Khattri S, Kumbargere Nagraj S, Arora A, Eachempati P, Kusum CK, Bhat KG, Johnson TM, Lodi G. Adjunctive systemic antimicrobials for the non-surgical treatment of periodontitis. Cochrane Database Syst Rev. 2020 Nov 16;11(11):CD012568. doi: 10.1002/14651858.CD012568.pub2.
Clinical trial NCT01054612: Tissue Sectioning by Electro-Dissociation
Official title: Tissue Sectioning by Electro-Dissociation
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Thin Sections
Fresh Unfixed Tissues
Fresh Unfrozen Tissues
Keywords: Histology
Immunohistochemical
Gene Expression
Tissue Sectioning
Lead sponsor: University of Arkansas
Sponsor class: OTHER
First posted: 2010-01-22
Enrollment: 0
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Sampling method: PROBABILITY_SAMPLE
Study population: Discarded human tissue obtained immediately following surgical resection

Brief summary: Currently there is no technique to produce thin (0.004-0.01 mm) serial sections of large fresh tissue specimens that are suitable for high-resolution in situ protein/gene expression studies without ice artifact or fixation-induced molecular damage. Traditional frozen sectioning preserves protein and nucleic acid structure, but the inherent ice artifact precludes reconstruction of protein and mRNA expression patterns in 3-dimensions. Since the limitations of the existing sectioning techniques result from the fact that they rely on mechanical cutting which in turn require the tissue to be stiff, we suggest a new approach to cut tissue via an electro erosion process that utilizes focus radio frequency (RF).


Eligibility criteria: Inclusion Criteria:

* Fresh Tissue
* Unfrozen Tissue
* Unfixed Tissue

Exclusion Criteria:

* Unfresh Tissue
* Frozen Tissue
* Fixed Tissue

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: UAMS, ACH, Central Arkansas Veterans Healthcare System
name: Gal Shafirstein, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04016012: Overweight and Obesity in Relation to Type ll Diabetes Melitus
Official title: Overweight and Obesity in Relation to Type II Melitus,Diabetes A Randomised Controlled Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Diabetes Mellitus, Type 2
Overweight and Obesity
Lead sponsor: Mukuba University
Sponsor class: OTHER
Collaborators: name: University of Zambia
name: Afe Babalola University, Nigeria
name: Buea University, Cameroon
name: Sokoine University of Agriculture
name: Kitwe Teaching Hospital, Zambia
name: National Science and Technology Council
First posted: 2019-07-11
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: The intervention group will receive a diabetic controlled diet using local Zambian foods for 8 weeks and standard health care for 8 weeks while the control group will eat their usual food in their home and receive standard health care for eight (8) weeks.
Primary purpose: TREATMENT

Brief summary: The aim of the study is to evaluate the efficacy of local Zambian food in improving metabolic profiles of overweight/obese type ll diabetic patients in Kitwe district


Eligibility criteria: Inclusion Criteria:

* Diabetic patients attending Kitwe Teaching Hospital
* 18 years and above
* Body Mass Index of 25 and above
* Willing to follow the diet plan and eat food provided
* Not enrolled in other clinical studies

Exclusion Criteria:

* Eating disorder or any psychosocial or scheduling factors that could impede study outcomes
* Have renal or liver problem
* Pregnant women
* Breast feeding women
* HIV positive individuals

Primary outcomes:
measure: Change in Blood glucose levels
timeFrame: At baseline and 8 weeks
Secondary outcomes:
measure: Change in Body weight
timeFrame: At baseline and 8 weeks
measure: Change of Body Mass Index (BMI)
timeFrame: At baseline and 8 weeks
Other outcomes:
Locations:
city: Kitwe
country: Zambia
facility: Kitwe Teaching Hospital
state: Copperbelt
Study officials:
affiliation: Mukuba University, Kitwe, Zambia
name: Given Chipili
role: PRINCIPAL_INVESTIGATOR
References: